Bronchiectasis Market Size and Trend Report including Epidemiology and Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2021-2031
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Bronchiectasis Market Overview
The Bronchiectasis market size was valued at $408.2 million across the 3MM in 2021. The market is expected to grow at a CAGR of more than 8% during the forecast period. AMD is one of the leading causes of irreversible vision loss. Bronchiectasis is defined by the damage to the bronchi, causing abnormal dilation and scarring. The airways become inflamed with thick mucus that is difficult to clear, whose build up creates an environment for bacterial growth. This uncontrolled bacterial growth leads to frequent infections. The cycle of repeated infections can, in turn, cause further damage to the airways. Bronchiectasis can occur throughout the lung or in a single section of the lung.
The Bronchiectasis market research report provides an overview of the risk factors, comorbidities, and global and historical trends for Bronchiectasis in the three major markets (3MM: US, Germany, and UK). It also includes a 10-year analytical forecast for total global sales of Bronchiectasis. The total and forecasted prevalent drug sales of Bronchiectasis are further segmented by age, sex, and stage in these markets.
Bronchiectasis Market Overview
To gain more information on the Bronchiectasis market forecast, download a free report sample
Key Bronchiectasis Market Drivers
The major driver for the Bronchiectasis market growth will be the anticipated high cost of therapy for new first in-class procedures. Continued usage of symptomatic drug classes such as antibiotics, mucolytics, and bronchodilators, and the lack of available disease modifying treatments will be the strongest driver of the market in the 3MM.
Key Sex Segments in the Bronchiectasis Market
The Bronchiectasis market can be segmented based on sex into men and women.
In the 3MM combined, the number of diagnosed prevalent cases of Bronchiectasis was higher in women than in men in 2021. However, the US had the highest number of diagnosed prevalent cases of Bronchiectasis. Germany had the smallest variation in the number of diagnosed prevalent cases between men and women.
Bronchiectasis Market Analysis by Sex
For more sex segment insights, download a free report sample
3MM Country-Wise Outlook of the Diagnosed Prevalent Cases in the Bronchiectasis Market
The US is anticipated to experience the fastest growth during the forecast period followed by UK, and Germany.
Bronchiectasis Market Analysis by Countries
For more insights on the country-wise outlook, download a free report sample
Unmet Needs in Bronchiectasis
- Lack of approved therapies: There are some pipeline agents such as Fasenra and brensocatib in late-stage development however, there has historically been a high trial failure rate in bronchiectasis.
- Improved Diagnostic Methods: Bronchiectasis is a very heterogenous condition and the only way to accurately diagnose it is through a CT scan, which is expensive and can place a burden on healthcare budgets and systems.
- Increased Awareness and Education: A lack of knowledge among patients and physicians keeps the diagnosis challenging, resulting in many undiagnosed cases and patients who do not seek treatment.
Key Players in the Bronchiectasis Market
Some of the key players in the Bronchiectasis market are AstraZeneca, Insmed, KamadaPharma, Zambon Pharma, and Novartis.
Bronchiectasis Market Report Scope
Market size (Year – 2021) | $408.2 million |
Growth rate (CAGR) | >8% |
Forecast period | 2021-2031 |
Key Sex Segments | Men and Women |
Key Countries | US, UK, and Germany |
Key Players | AstraZeneca, Insmed, KamadaPharma, Zambon Pharma, and Novartis |
Scope
- Overview of Age-Related Macular Degeneration – including epidemiology, disease etiology, and management.
- Topline Bronchiectasis drugs market revenue, the annual cost of therapy, and anticipated sales for major late-stage pipeline drugs.
- Key topics covered include assessment of current and pipeline therapies, unmet needs, current and future players, and market outlook for the US, UK, and Germany over the 10-year forecast period.
- Pipeline analysis: Emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
- Analysis of the current and future market competition in the global Bronchiectasis therapeutics market. Insightful review of the key industry drivers, restraints, and challenges
Reasons to Buy
The report will enable you to:
- Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.
- Develop business strategies by understanding the trends shaping and driving the global Bronchiectasis therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Bronchiectasis market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter strategies to gain a competitive advantage.
- Track drug sales in the global Bronchiectasis therapeutics market from 2021 to 2031.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Table of Contents
Frequently asked questions
-
What was the Bronchiectasis market size in 2021?
The Bronchiectasis market size was valued at $408.2 million in 2021 across the 3MM.
-
What is the Bronchiectasis market growth rate?
The Bronchiectasis market is forecast to grow at a CAGR of more than 8% during the forecast period.
-
What are the key sex segments in the Bronchiectasis market?
The Bronchiectasis market can be segmented based on sex into men and women.
-
What are the key countries in the Bronchiectasis diagnosed prevalent cases?
The US is anticipated to experience the fastest growth in the Bronchiectasis cases, during the forecast period, followed by UK, and Germany.
-
Who are the key players in the Bronchiectasis market?
Some of the key players in the Bronchiectasis market are AstraZeneca, Insmed, KamadaPharma, Zambon Pharma, and Novartis.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.